Igor Grosman, DO
Gastroenterology · Brooklyn, NYNPI 1851506869
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $64,450 of the $77,304 with a category attached, or 83.4%. AbbVie accounts for 88.5% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2019 at $27,258 and has fallen 98.6% since, to $390 in 2025. Among gastroenterology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 730 payments — averaging $105.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$68K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Gilead$1K
- Bristol Myers Squibb$822
- Pfizer$521
- Takeda Pharmaceuticals U.S.A., Inc.$379
- plus $4K from 34 others
Across 295 payments — averaging $9363.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ironwood Pharmaceuticals, Inc$1.1M
- AbbVie$973K
- Braintree Laboratories, Inc.$366K
- Hikma Pharmaceuticals USA$81K
- Eli Lilly$55K
- Phathom Pharmaceuticals, Inc.$54K
- plus $137K from 6 others
What the payments were for
- Consulting fees$210%
- Speaking & faculty fees$64,45083%
- Food & beverage$12,83317%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$77,304 in reported general payments places this provider in the 90th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 202 | $434,626 |
| ZenpepLipase/Protease/Amylase | 74 | $184,504 |
| XifaxanRifaximin | 45 | $118,442 |
| LinzessLinaclotide | 128 | $81,034 |
| OzempicSemaglutide | 17 | $26,300 |
| Dexlansoprazole DrDexlansoprazole | 156 | $24,468 |
| VoqueznaVonoprazan Fumarate | 23 | $14,450 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 15 | $13,909 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 222 | $12,780 |
| Sucralfate | 176 | $8,127 |
| MotegrityPrucalopride Succinate | 14 | $7,961 |
| DexilantDexlansoprazole | 22 | $6,387 |
| TrulancePlecanatide | 12 | $6,240 |
| Mesalamine ErMesalamine | 37 | $6,234 |
| Mesalamine | 21 | $4,265 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $68,438 | $515,660330 claims |
| Aimmune Therapeutics, Inc.Zenpep | $140 | $184,50474 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $2,397 | $124,68257 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $102 | $14,45023 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity, Dexilant | $379 | $14,34836 claims |
| Braintree Laboratories, Inc.Sutab, Suflave | $93 | $3,43925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,682 gastroenterology providers in New York.
Other gastroenterology in Brooklyn
- Sam MoskowitzBrooklyn$332K
- Jianjun LiBrooklyn$211K
- Nison BadalovBrooklyn$200K
- Kevin TinBrooklyn$168K
- Jonathan ErberBrooklyn$164K
- Rabin RahmaniBrooklyn$155K
- Kayane Hanna-HindyBrooklyn$151K
- Kadirawelpillai IswaraBrooklyn$148K
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.